RxDoctor Payments Data

Inez Stoltzfus, MD

Family Medicine · Thorndale, PANPI 1063587558

Payments from drug & device makers

$6,166in general payments, 2019–2025

Across 372 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$874
  • AstraZeneca$517
  • Pfizer$309
  • Amgen$304
  • Lilly USA, LLC$278
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,160100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,166 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$286,233
Medicare patients
538
Services billed
9,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$96,057
EliquisApixaban85$85,254
MounjaroTirzepatide41$57,390
RybelsusSemaglutide44$50,576
FarxigaDapagliflozin Propanediol48$38,894
TrulicityDulaglutide14$35,098
JardianceEmpagliflozin20$28,003
MyrbetriqMirabegron32$26,492
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$25,097
Bydureon BciseExenatide Microspheres14$24,296
JanuviaSitagliptin Phosphate16$21,017
LinzessLinaclotide13$18,146
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$16,861
XareltoRivaroxaban19$16,313
Breo ElliptaFluticasone/Vilanterol21$12,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$874$146,633100 claims
Lilly USA, LLCMounjaro, Trulicity$278$92,48755 claims
PfizerEliquis$309$85,25485 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$266$45,08074 claims
AstraZenecaFarxiga$517$38,89448 claims
Boehringer IngelheimJardiance$101$28,00320 claims
MerckJanuvia, Belsomra$124$26,92428 claims
Astellas Pharma US IncMyrbetriq$226$26,49232 claims
AbbVieLinzess, Synthroid$1,224$21,67067 claims
Johnson & JohnsonXarelto$50$16,31319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Thorndale

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →